Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
Erişim
info:eu-repo/semantics/closedAccessTarih
2023Yazar
Lavie, DavidTimmerman, John
Garcia-Sanz, Ramon
Kim, Won Seog
Kim, Tae Min
Avigdor, Abraham
Dierickx, Daan
Jagadeesh, Deepa
Molin, Daniel L.
Herrera, Alex F.
Üst veri
Tüm öğe kaydını gösterKünye
Lavie, D., Timmerman, J., Garcia-Sanz, R., Kim, W. S., Kim, T. M., Avigdor, A. ... Herrera, A. F. (2023). Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008. 65th Annual Meeting of the American-Society-of-Hematology (ASH). San Diego, CA, 09-12 December, 2023. https://dx.doi.org/10.1182/blood-2023-182119Özet
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. However, most patients eventually develop progressive disease and optimal therapy after anti-PD-1 failure has not been determined. The inhibitory checkpoint receptor, lymphocyte-activation gene 3 (LAG-3) is expressed in cHL tumor microenvironments and upregulation of LAG-3 is considered to play an important role in anti-PD-1 resistance. Favezelimab (MK-4280) is a humanized immunoglobulin G4 antibody that binds to LAG-3 and blocks interaction with major histocompatibility complex Class II ligands. Results from the ongoing phase 1/2 MK-4280-003 study of the combination of favezelimab and pembrolizumab demonstrated manageable safety and promising antitumor activity in patients with anti-PD-1-refractory R/R cHL. The randomized, open-label, parallel group, active-controlled, phase 3 KEYFORM-008 study (NCT05508867) is designed to evaluate efficacy and safety of the coformulation of favezelimab and pembrolizumab versus physician's choice of chemotherapy in patients with anti-PD-1-refractory R/R cHL.
WoS Q Kategorisi
Q1Kaynak
65th Annual Meeting of the American-Society-of-Hematology (ASH)Cilt
142Sayı
1Koleksiyonlar
- Bildiri Koleksiyonu [515]
- WoS İndeksli Yayınlar Koleksiyonu [6516]